Stock comparison
Eton Pharmaceuticals
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ETON
Eton Pharmaceuticals
Market cap
$892.72M
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ETON | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 17F | 79B | HALO |
| Benjamin Graham | 44D | 83A | HALO |
| Philip Fisher | 40D | 65B | HALO |
| Peter Lynch | 46D | 53D | HALO |
| Joel Greenblatt | 0F | 40D | HALO |
| Charlie Munger | 22F | 80C | HALO |
| Terry Smith | 22F | 84A | HALO |
Side-by-side metrics
| Metric | ETON | HALO |
|---|---|---|
| Market cap | $892.72M | $8.1B |
| P/E (TTM) | - | 24.0x |
| EV/EBIT | 11026.8x | 10.2x |
| ROIC (TTM) | -1.35% | 23.65% |
| Gross margin | 53.46% | 81.24% |
| Net margin | -5.75% | 23.13% |
| Revenue CAGR 5y | 38.33% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | 0.4x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ETON leads on
- P/E (TTM)-vs 24.0x+114%
- Debt / Equity0.4xvs 1.0x+63%
- Revenue CAGR 5y38.33%vs 33.23%+13%
HALO leads on
- Net margin23.13%vs -5.75%+125%
- ROIC (TTM)23.65%vs -1.35%+106%
- EV/EBIT10.2xvs 11026.8x+100%
- Market cap$8.1Bvs $892.72M+89%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.